TABLE 1.
Characteristics of HIV-2-infected individuals
| Patient | Nationalitya | HIV-2 subtype | Follow-up (mo)b | CDC stagec | CD4/μlc | RNA/mlc | Total fu (mo/yr)d | No. of clones analyzed |
|---|---|---|---|---|---|---|---|---|
| Aviremic HIV-2 infection | ||||||||
| RH2-3 | CVI | A | 96.2 | A1 | 770 | <500 | 126.8/10.6 | 10 |
| RH2-4 | NL | A | 85.5 | A1 | 860 | <500 | 112.3/9.4 | 3 |
| RH2-8 | GH | B | 80.3 | A1 | 900 | <500 | 106.9/8.9 | 1 |
| RH2-13 | CVI | A | 52.0 | A1 | 900 | <500 | 82.4/6.9 | 10 |
| RH2-14 | CVI | A | 50.7 | A1 | 550 | <500 | 75.1/6.3 | 9 |
| RH2-22 | CVI | B | 30.0 | A1 | 670 | <500 | 46.6/3.9 | 10 |
| Viremic HIV-2 infection | ||||||||
| RH2-15a | GB | A | 20.8 | A2 | 410 | 1,300 | 70.8/5.9 | 2 |
| RH2-15b | GB | A | 42.9 | A2 | 400 | 14,000 | 70.8/5.9 | 3 |
| RH2-1 | CVI | A | 56.5 | C1 | 240 | NT | NA | 6 |
| RH2-5 | CVI | A | 38.0 | C3 | 120 | 110,000 | NA | 6 |
| RH2-7 | CVI | A | 32.5 | A3 | 10 | + | NA | 6 |
| RH2-21 | CVI | A | 1.4 | C3 | 60 | 59,000 | NA | 2 |
| RH2-24 | CVI | A | 3.8 | A3 | 70 | 23,000 | NA | 10 |
| RH2-26 | NL | B | 0.9 | C3 | 10 | 330,000 | NA | 10 |
a
CVI, Cape Verde Islands; GH, Ghana; GB, Guinea Bissau; NL, Netherlands.
b
Time between first visit to the clinic and the sample of virus isolation.
c
CDC stage, CD4 numbers and RNA copies at the time point of virus isolation, except RH2-4, RH2-21, and RH2-24, in which cases the previous time point (viremic individuals) or the next time point (aviremic individual) was taken. The time points of virus isolation and CD4/RNA determination were always maximally 6 months apart. NT, not tested; +, positive.
d
Follow-up (fu) until the last visit to the clinic by August 2003 for the asymptomatic individuals. NA, not applicable.